Stoke Therapeutics, Inc. financial data

Symbol
STOK on Nasdaq
Location
Bedford, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 04 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 697% % 17%
Debt-to-equity 16% % -51%
Return On Equity 13% %
Return On Assets 11% %
Operating Margin 13% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 57,117,150 shares 7.8%
Common Stock, Shares, Outstanding 55,120,002 shares 4.1%
Entity Public Float $528,000,000 USD 82%
Common Stock, Value, Issued $5,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 58,611,677 shares 4%
Weighted Average Number of Shares Outstanding, Diluted 58,611,677 shares 4%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $205,632,000 USD 1128%
Research and Development Expense $119,651,000 USD 37%
General and Administrative Expense $55,452,000 USD 26%
Operating Income (Loss) $27,194,000 USD -44%
Nonoperating Income (Expense) $13,373,000 USD 13%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $39,625,000 USD -50%
Income Tax Expense (Benefit) $1,278,000 USD
Net Income (Loss) Attributable to Parent $40,567,000 USD -45%
Earnings Per Share, Basic 0 USD/shares -38%
Earnings Per Share, Diluted 0 USD/shares -38%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $83,394,000 USD -44%
Accounts Receivable, after Allowance for Credit Loss, Current $9,248,000 USD
Other Assets, Current $5,543,000 USD 46%
Assets, Current $272,437,000 USD 7.4%
Property, Plant and Equipment, Net $3,083,000 USD -29%
Operating Lease, Right-of-Use Asset $3,708,000 USD -25%
Assets $360,264,000 USD 23%
Accounts Payable, Current $5,871,000 USD 136%
Liabilities, Current $41,727,000 USD -16%
Operating Lease, Liability, Noncurrent $1,874,000 USD -38%
Other Liabilities, Noncurrent $1,874,000 USD -39%
Liabilities $52,159,000 USD -15%
Accumulated Other Comprehensive Income (Loss), Net of Tax $446,000 USD 169%
Retained Earnings (Accumulated Deficit) $439,781,000 USD 8.4%
Stockholders' Equity Attributable to Parent $308,105,000 USD 33%
Liabilities and Equity $360,264,000 USD 23%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $131,827,000 USD
Net Cash Provided by (Used in) Financing Activities $1,374,000 USD -20%
Net Cash Provided by (Used in) Investing Activities $13,632,000 USD 36%
Common Stock, Shares Authorized 300,000,000 shares 0%
Common Stock, Shares, Issued 55,120,002 shares 4.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $146,833,000 USD
Deferred Tax Assets, Valuation Allowance $165,559,000 USD 24%
Deferred Tax Assets, Gross $165,559,000 USD 24%
Operating Lease, Liability $4,782,000 USD -9.9%
Depreciation $477,000 USD -15%
Payments to Acquire Property, Plant, and Equipment $152,000 USD 1167%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $40,847,000 USD -45%
Lessee, Operating Lease, Liability, to be Paid $5,204,000 USD -11%
Property, Plant and Equipment, Gross $12,757,000 USD 2.1%
Operating Lease, Liability, Current $2,908,000 USD 27%
Lessee, Operating Lease, Liability, to be Paid, Year Two $3,250,000 USD 22%
Lessee, Operating Lease, Liability, to be Paid, Year One $780,000 USD 19%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $422,000 USD -26%
Lessee, Operating Lease, Liability, to be Paid, Year Three $701,000 USD -73%
Deferred Tax Assets, Operating Loss Carryforwards $70,105,000 USD 33%
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $473,000 USD
Additional Paid in Capital $747,435,000 USD 4.9%
Share-based Payment Arrangement, Expense $29,529,000 USD 12%
Interest Expense $6,000 USD